Please assess the completion status of the following clinical trial:

Trial Title: Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NSTE-ACS~* Male, 50-80 years old~* Female, postmenopausal age~Exclusion Criteria:~* Female, premenopausal age~* autoimmune disease~* infectious disease~* neoplasms~* diabetes~* chronic renal failure~* moderate or severe liver insufficiency~* GRACE risk score\>140~* ACS or cerebrovascular accidents in previous three months~* in-stent restenosis~* surgery or trauma in previous three months~* active bleeding~* fibrinolytic therapy within 24 hours before randomization~* need for oral anticoagulation therapy~* an increased risk of bradycardia~* drugs study hypersensitivity (including aspirin)~* co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: ACTIVE_COMPARATOR): Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).